At the intersection of metallomics and drug development, ZNA Oncology pioneers with an innovative isotope-selective modulation (ISM) class of immunotherapy, which fights tumors by increasing wtp53 levels and inducing T-cell activity.  Our over a decade-long research, preclinical results, and initial clinical data provide strong scientific rationale for the development of inherently safe and clinically significant medicines that assist in correct protein conformation, improve mitochondrial function, and possibly reduce racemization of d-amino acids. Our drug candidates alter the isotopic signatures of biological cells and tissues, to not only target malignant tumors, but also to promote regeneration of healthy cells and tissues, all while maintaining a steadfast commitment to patient safety. 

Metallomics integrates chemistry, biology, physics, and medicine focusing on the roles of metals in biological systems. It examines the metallome - the full spectrum of metals withing cells and organisms - using advanced mass spectrometry to uncover metal concentrations, distributions, and interactions. Metallome is crucial for understanding diseases linked to metal imbalances, such as neurodegenerative disorders, and for exploring the fundamental processes of life. Unlike conventional medications that typically interact with their targets on a surface level, thereby managing symptoms rather than the root cause, our isotope-selective modulation operates within the principles of a multi-omic approach, which empowers us to create drugs that holistically influence critical biological processes, ranging from protein synthesis and DNA repair to mitochondrial function.

The insights from metallomics are revolutionizing drug discovery by identifying new therapeutic targets and improving drug delivery. Metallomics also supports the development of precision medicines by tailoring treatments to metallomic profiles, enhancing drug delivery and safety. We believe that the exploration of metal isotopes for targeted therapies further amplifies the innovative applications of metallomics in creating more precise and less toxic drugs and promises to be a key driver in the development of advanced medical treatments. The inherent safety profile of stable light isotopes in metallome highlights its transformative potential in the pharmaceutical industry, promising new era of treatments that are both more effective and clinically safe.